Type 1 diabetes is a complex disease that has both genetic and environmental determinants. Based on twin and family studies, the estimated contribution of genetic factors to type 1 diabetes risk is ~50%. Genes and their variants within the human major histocompatibility complex (MHC), including the human leukocyte antigen (HLA) class I (HLA-A, -B, and -C) and class II (HLA-DR, -DQ, and -DP) loci, account for about one-half of the genetic risk of type 1 diabetes. Three amino acid positions in HLA-DQ and HLA-DR define ~90% of the variation in the MHC, with evidence of interactions between pairs of HLA haplotypes that affect antigen binding. Other major contributors to type 1 diabetes genetic risk have been identified through candidate gene and linkage studies and include variants in or near the INS, CTLA4, IL2RA, and PTPN22 genes. Genome-wide association approaches have revealed additional loci containing common variants with relatively small individual effects on type 1 diabetes risk. International efforts led by the Type 1 Diabetes Genetics Consortium and others have identified over 40 non-MHC loci and narrowed the likely candidate genes and variants substantially. The majority of non-MHC variants affect gene regulation rather than directly altering protein structure. Both analytic and molecular work are required to assess the functional significance of the variants in type 1 diabetes susceptibility genes in order to identify critical biologic pathways that could lead to novel interventions and therapeutics.
INTRODUCTION
The natural history of type 1 diabetes is based on precipitating events in an individual with genetic susceptibility. The evidence for genetic factors contributing to type 1 diabetes risk comes from twin and family studies that estimate the familial aggregation of the disease based on risk in relatives of an affected individual. In monozygotic twins, who share 100% of their genes, when a member of the pair has type 1 diabetes, the risk to the co-twin is ~50%, suggesting that both genetic and nongenetic factors contribute to risk (1) . This concordance increases to 65% by age 60 years and 89% for autoantibody-positive pairs (2) . Presence of high-risk genotypes of the human leukocyte antigen (HLA) loci (HLA-DR3, -DR4) in the major histocompatibility complex (MHC) (3) and the INS gene (4) are found in higher frequency in concordant pairs, suggesting a major impact of genetic factors and heterogeneity in concordance rates. The population risk is decreased to ~8% in dizygotic twin pairs, similar to the risk observed for siblings, who also share 50% of their genes, but have a lesser extent of common environmental exposures than twins. In population studies, the estimated prevalence of type 1 diabetes in non-Hispanic whites is approximately 4 per 1,000; thus, the increased risk in siblings (8%) relative to the prevalence in the general population (4/1,000) is consistent with a major genetic contribution to type 1 diabetes risk (5, 6) . Type 1 diabetes is most common in non-Hispanic whites (i.e., populations of European ancestry); it also occurs in those of African, Hispanic, and Asian ancestry but at decreasing prevalence and incidence. Despite extensive epidemiologic data on prevalence of type 1 diabetes in varied ethnic groups, there is a critical absence of data on risk to siblings in diverse populations, preventing estimation of genetic impact on type 1 diabetes risk in nonwhite populations. Although nearly one-half of type 1 diabetes in non-Hispanic white populations is diagnosed after age 20 years, there is a similar absence of information on the risk to siblings of adultonset type 1 diabetes. This lack of data can be attributed to the concept that onset of diseases (e.g., type 1 diabetes) early in life is more likely to be "genetic" than when the disease has onset later in life. As a result, estimates of the impact of genetic factors on risk of type 1 diabetes in adults (of any population ancestry) are lacking.
The genetic risk ratio in siblings (λ S ), defined by the ratio of the sibling risk to the population prevalence, is ~16 in type 1 diabetes of European ancestry (7), much higher than that in type 2 diabetes, for example, yet this figure provides no insight into either the number of genes contributing to type 1 diabetes risk or the sizes of their effects. Although ~50% of the risk of type 1 diabetes can be attributed to genetic (familial) factors, an additional question can be asked about the extent of this genetic risk accounted by specific genes and their variants. For example, in families with two children with type 1 diabetes, the expectation under the hypothesis that a variant in a gene has no effect on type 1 diabetes risk is that 25% of sibling pairs would share both copies of the variant (same genotype), 50% would share one copy of the variant in the genotype, and 25% would share no copies of the variant (completely different genotypes). In fact, the risk to siblings who share two HLA haplotypes is 55%, much greater than 25%, indicating that a significant proportion of the total genetic risk can be attributed to the HLA region (7).
The recognition that ~50% of risk for type 1 diabetes was genetic and approximately one-half of the genetic risk was due to factors in the MHC provided the stimulus for two subsequent research paths. The first was to delineate the specific genes and mechanisms in the MHC (the HLA genes and also other genes and variants) that account for the majority of type 1 diabetes genetic risk. The second was to identify the non-MHC genes that account for the remaining 50% of genetic risk for type 1 diabetes. Two primary study designs were used for these efforts: family-based (typically families with two parents and two type 1 diabetes-affected children) and case-control (a series of type 1 diabetes cases and a series of unaffected controls). The family-based designs were used for linkage analyses (co-segregation of the alleles transmitted from the parents to the affected children, with evidence of increased sharing of genotype in the affected children) or for association in the presence of linkage analyses (alleles transmitted from parents to affected offspring are "case" alleles, while those not transmitted are "control" alleles). The case-control approach was used to determine the frequency of the alleles in cases and controls, with a significant difference in frequency suggesting an association with type 1 diabetes for that genetic variant. As collection of large numbers of affected sibpair (ASP) families (for robust statistical power) was difficult, much of the genetic evaluation of genes contributing to type 1 diabetes employed a case-control design. The following sections expand on the evolution of the genetic technology and findings related to the genetic basis of type 1 diabetes.
MAJOR HISTOCOMPATIBILITY COMPLEX AND TYPE 1 DIABETES RISK
Early efforts (i.e., 1970s to 2000) to localize and identify genes that contribute to the occurrence of type 1 diabetes, as well as other autoimmune diseases, focused on genes involved in the immune response. Obvious candidates, in this regard, were genes encoding the highly polymorphic HLA molecules that play critical roles in the immunologic distinction between self and non-self, as well as in the presentation of antigens to the cellular immune system. In humans, the MHC is a gene-rich region on chromosome 6p21.3 that includes genes encoding the HLA class I (HLA-A, -B, and -C) and class II (HLA-DR, -DQ, and -DP) molecules (Figure 12 .1). The importance of the MHC in type 1 diabetes risk is likely through its role in the presentation of peptide antigens to T cells; genetic variation in this system could act centrally by interfering with the tolerance of lymphocytes during their maturation in the thymus, or peripherally by altering the repertoire of antigens presented. The immune response is centered on antigen presentation, in which foreign antigens are recognized by antigen-presenting cells (APCs), processed into peptides, complexed to the MHC, and presented on the cell surface, where they can potentially be recognized by T cells (Figure 12. 2). As the T cell does not recognize "free" foreign peptides, the processing requires APCs and the action 
. Antigen Presentation and T Cell Activation
Antigen is linked to APC via multiple mechanisms (step 1) followed by MHC class II recognition, antigen processing (step 2), and presentation to T cells for removal (step 3). APC, antigen-presenting cell; MHC, major histocompatibility complex.
SOURCE: Reference 45, copyright © 2012 Frontiers, reprinted with permission of a number of other genes, some also located in the HLA region, to complex the peptide with MHC. Thus, a critical aspect of protection is the ability of the MHC to provide a broad array of options to receive the foreign peptide, with these options defined by genetic variation.
The genes in the MHC contain many alternative forms (many alleles) and thereby provide extensive variation in humans, perhaps the most variable in the human genome. This variation is critical, as the MHC controls a major part of the human immune response through the interactions of its cell surface molecules with other molecules or peptides (both from itself and from external sources). The presence of many alleles in each of the HLA genes (class I and class II) makes it highly likely that any two individuals in a population (except for monozygotic twins) have a different combination of MHC alleles. Most cells in the body can use MHC class I molecules to present foreign peptide to (CD8+) T cells and "act" as APCs. Typically, the APCs internalize the foreign peptide and display a fragment bound to an MHC class II molecule on the cell surface (Figure 12 .2). The T cell will then recognize this complex and initiate T cell activation. This becomes critical as the focus of the MHC is on immune surveillance. Thus, while there can be relatively broad ability for the MHC to recognize a broad array of peptides, there can also be specificity as to which peptides are bound. The variation permits both a broad response to peptides with a few highly variable genes and also provides protection in a population of individuals from a new foreign peptide due to extreme diversity.
The initial report of a strong association of HLA with type 1 diabetes occurred in 1973 with alleles of the class I HLA-A (or, then, HL-A) locus (8) . Many reports confirmed and extended the association of type 1 diabetes with antigens/alleles of the class I (HLA-A and -B) and class II (HLA-DR, -DQ, and -DP) loci. Importantly, the structure of the MHC on 6p21.3 contains a cluster of HLA loci that are physically close (within 4 Mb, Figure 12 .1) and, therefore, genetically correlated (in linkage disequilibrium, LD). The extent of the LD in the MHC spans the ~4 Mb interval and results in the transmission of HLA "haplotypes" from parent to child. As LD is the occurrence of some combinations of alleles at adjacent loci more (or less) often than expected from the frequencies of the individual alleles, groups of alleles on a chromosomal segment can be inherited as a unit, or as a haplotype. The human MHC exhibits strong LD and specific HLA haplotypes are associated with type 1 diabetes risk and provide a "fingerprint" of the transmission of disease-associated variation across populations.
Although statistical methods can be used to construct HLA haplotypes from unrelated individuals, the most precise method for observation and estimation of haplotypic association comes from family studies. As noted above, family studies have been conducted in non-Hispanic white populations, with a high prevalence and typically restricted to those probands with onset of type 1 diabetes before age 16 years (but onset up to age 35 years in siblings). A common measure of association is the odds ratio (OR), an epidemiologic statistic that measures the relationship between an exposure (in this case, genotype or haplotype) and an outcome (type 1 diabetes). As the odds ratio is used to compare the relative odds of the outcome given the exposure, it can be interpreted as "risk" (OR >1), "protection" (OR <1), or neutral (OR 1 (10, 13) .
HLA allele and haplotype frequencies differ among populations, perhaps contributing to the differences in type 1 diabetes prevalence across geographic areas. A North-South gradient in type 1 diabetes prevalence has been observed, with Scandinavians having the highest type 1 diabetes risk. Sardinia, however, has a very high type 1 diabetes risk, due in part to the founder effect that established particularly high frequencies of the type 1 diabetes-susceptible HLA-DR3 and HLA-DR4 alleles and haplotypes and the low frequency of the type 1 diabetes-protective HLA-DR2 allele and haplotype (14) .
Further complexity in the MHC and risk of type 1 diabetes has been uncovered. Variation in the genes encoding the HLA-DR and HLA-DQ molecules is associated with risk of type 1 diabetes with odds ratios in excess of 10 for susceptible genotypes (e.g., DR3/DR4 or DRB1*03:01-DQB1*02:01/ DRB1*04-DQB1*03:02) or less than 0.1 for protective genotypes (e.g., DR2/DRX, where "X" is neither DR3 nor DR4 [or DR2]; the dominantly protective haplotype is DRB1*15:01-DQB1*06:02). The class II molecules encoded by these genes combine to form heterodimeric (αβ) protein receptors that are typically expressed on the surface of APC. HLA-DQ is determined by a polymorphic α-chain (encoded by HLA-DQA1 locus) and a polymorphic β-chain (encoded by HLA-DQB1 locus). In contrast, HLA-DR is determined by a monomorphic α-chain (encoded by the HLA-DRA locus) paired with a highly polymorphic β chain. Most DR haplotypes in the population contain two loci: DRB1 and a second DRB locus (either DRB3, DRB4, or DRB5). A few DR haplotypes (e.g., DRB1*01, DRB1*08, and DRB1*10) do not have a second DRB locus. A heterozygous individual could encode up to four different DRB molecules (15) . Thus, type 1 diabetes risk is determined by specific genotype combinations; for example, the genotype HLA-DRB1*03(HLA-DQB1*02)/ HLA-DRB1*04(HLA-DQB1*03:02) confers the highest risk and has the highest frequency in type 1 diabetes cases with youngest onset.
The allelic variations in the critical HLA class II genes (HLA-DRB1, HLA-DQA1, and HLA-DQB1) are thought to alter specific amino acid residues that affect binding of foreign peptides leading to initiation of the autoimmune disease process. Only recently have independent amino acid positions and large-scale genetic studies been available to examine the contribution of HLA class II alleles and their interactions in type 1 diabetes (16) . In a large series of European cases, controls and families, over 7,000 single nucleotide polymorphisms (SNPs) and amino acid residues at 399 positions for eight HLA genes were examined. As expected, the single most associated risk variant was HLA-DQB1*03:02 that encodes an alanine at HLA-DQβ1 position 57, while the aspartic acid at this position is most protective. The second independent association is at HLA-DRβ1 position 13, where a histidine residue (tagging HLA-DR4) confers risk (arginine is protective), as does a serine residue that tags HLA-DR3 (tyrosine is protective). The HLA-DRβ1 residue at position 71 is a third independent association, with lysine conferring strong risk (tagging HLA-DR3 and HLA-DR4), while an alanine residue at this site is protective (Figure 12. 3) (16). (16) . Thus, together these three amino acid positions capture ~27% of type 1 diabetes risk, or ~80% of the MHC-associated risk. The total type 1 diabetes risk explained by independent (additive) effects in the classical HLA genes is ~34% (Figure 12 .5). Structurally, the known association of HLA-DQβ1 position 57 would alter the HLA-DQ P9 pocket; however, the novel associations with the HLA-DRβ1 position 13 and HLA-DRβ1 position 71 sites would alter the HLA-DR P4 pocket. This structural site may be important in binding specific autoantigens that are associated with type 1 diabetes risk.
Although the influence of HLA class II genes on type 1 diabetes risk remains unquestioned, significant residual evidence of association with type 1 diabetes can be detected in the MHC region after controlling for the effects of HLA class II loci (16) . Analysis of HLA haplotypes suggest that non-additive effects are common within the MHC. HLA-DQβ1 position 57 and HLA-DRβ1 position 13 are the strongest contributors to both additive and interactive effects on type 1 diabetes risk in the MHC (17) . These two strongest interacting positions are in separate HLA molecules (HLA-DQ for position 57 and HLA-DR for position 13).
In a detailed interaction analysis of the MHC, the effect of interaction within a site (dominance) was shown to have a small (~1%), but significant impact on the contribution to risk of type 1 diabetes (17) . Including interactions at the individual haplotypes, rather than alleles at a given site, resulted in an additional 3% of risk of type 1 diabetes. Together, the additive and interaction effects of the classical HLA sites and amino acid residues account for over 90% of the MHC-type 1 diabetes association.
NON-MAJOR HISTOCOMPATIBILITY COMPLEX RISK LOCI
The fundamental process by which genetic variation is associated with type 1 diabetes risk is through assessing DNA sequence variation that differs in type 1 diabetes cases and controls or through co-segregation with type 1 diabetes in families. One such DNA variant occurs when a single nucleotide in the genome differs in a population with greater than 5% frequency. This variant is then termed a single nucleotide polymorphism (SNP).
There are millions of SNPs throughout the human genome, roughly one SNP every 2,000 bases.
LINKAGE MAPPING
The primary focus of genome-wide linkage scans in type 1 diabetes was to identify regions of the genome that exhibited a significant deviation of "sharing" (identity-by-descent, IBD) by sibling pairs from that expected for Mendelian segregation of chromosomes (e.g., 25% sharing two alleles IBD, 50% sharing one allele IBD, 25% sharing no alleles IBD). In type 1 diabetes, this process was typically performed on multiple affected siblings in a family, with a large number of families required to achieve robust statistical power given the expected size of risk in non-MHC genes (18, 19 HLA  INS  PTPN22  IL2RA  C10orf59  SH2B3  ERBB3  COBL  PTPN2  CTRB1/2  CLEC16A  CTLA4  IL18RAP  PTPN2  IL10  CCR5  C6orf173  C14orf181  PRKD2  IFIH1  CTSH  CD226  IL27  GAB3  IL2RA  SKAP2  GLIS3  ORMDL3  PRKCQ  IL2  BACH2  UBASH3A  RGS1  IL7R  CIQTNF6  SIRPG  TNFAIP3  4p15  CD69 3,999 controls, followed by a combined meta-analysis with previously published studies that added a further 3,715 cases and 5,069 controls, with information from more than 841,622 SNPs. From the meta-analysis of 7,514 cases and 9,045 controls with confirmation in 4,267 cases, 4,670 controls, and 2,319 ASP families, 28 novel regions provided initial significant evidence for association to type 1 diabetes risk (26) . Eighteen novel regions were strongly replicated from the GWAS meta-analysis.
. Progress Mapping Type 1 Diabetes Susceptibility Genes Based on Era of Genomic Search
In total, the number of loci contributing significantly to risk of type 1 diabetes risk had now reached 42, although each locus varied in size of the interval, the number of candidate genes in the locus, the size of the effect on type 1 diabetes risk for the most associated SNP, and the strength of the evidence supporting the most likely candidate (Figure 12.6 ). This figure demonstrates several points. The T1DGC further examined the 18 novel loci by expansion of the family sample to account for potential population stratification and replication genotyping (27) . The analyses of these 2,322 additional families, combined with the original 2,319 families, provided improved protection from population stratification bias and increased power to provide further replication support for the associations of the 18 novel susceptibility loci. With this larger sample of families, only one (C14orf181/14q24.1) of the 18 novel loci failed to reach statistical significance. Further, all of the novel type 1 diabetes risk loci had consistent direction of effects (e.g., risk or protective for type 1 diabetes risk) with the original GWAS meta-analysis (26, 27) with no evidence of heterogeneity in the disease associations across family collections, despite there being significant SNP genotype frequency differences. After unequivocal replication of type 1 A GWAS seeks to capture genomic architecture with high information content using a standard set of SNPs. In contrast, fine-mapping requires saturation of specific regions of the genome, with the predetermined boundaries of each region defining the set of SNPs to be genotyped. In order to meet the needs of type 1 diabetes and other autoimmune diseases with genome-wide significant regions to be interrogated, the ImmunoChip consortium was established. The consortium consisted of investigators who provided data (including unpublished) to design a genotyping array (the ImmunoChip) for fine-mapping autoimmune disease susceptibility genes. The ImmunoChip is a custom Illumina Infinium high-density genotyping array consisting of 196,524 SNPs over 186 regions of the human genome.
For type 1 diabetes, the initial analyses of ImmunoChip data included 6,670 type 1 diabetes cases, 9,416 controls, 2,601 T1DGC ASP families, and 69 T1DGC trio (affected child and both parents) families (29) . A large proportion of these samples (98% of cases, 76% of controls, and 57% of family samples) were used in the previous GWAS meta-analysis that initially identified many of the type 1 diabetes regions (26) . Including those loci that were significantly associated with another autoimmune disease (but only nominally with type 1 diabetes), 55 non-MHC loci were evaluated. Of the non-MHC type 1 diabetes-associated regions, 36 were significantly associated with type 1 diabetes risk from the ImmunoChip data (including 33 of 45 that had been reported by the T1DGC or others previously); in addition, there were three loci that were nominally associated with type 1 diabetes that were also robustly associated with other autoimmune diseases (30) and were, therefore, included as type 1 diabetes loci ( (36) . In general, the number of coding variants and noncoding variants that potentially contribute to type 1 diabetes risk varies by gene region (Figure 12.7) . These data suggest that much work remains to be accomplished to identify the causal genes, the variants within the genes that modify risk, and the functional impact of those variants. 
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The most strongly associated SNP in a region is shown, together with the effect of the minor allele relative to the major allele. Alleles are shown as major allele>minor allele. rs689 (11p15.5, INS) data were obtained from previous TaqMan genotyping. Named candidate genes are genes for which there was additional evidence that they might be causal or which encode proteins with known immune functions that are part of the immune pathways already identified as being involved in type 1 diabetes pathogenesis. Because SNPs may alter enhancer sequences distant from the target gene, a gene (or a noncoding RNA) is not named if the only evidence for a causal role was that the peak of SNP association lies in or very near a gene (unless the SNPs alter coding sequence or splicing signals in a potentially functional way). For example, RNLS at 10q23.31 has no established role in the immune system, and there is currently no specific functional data linking this gene to type 1 diabetes etiology. ATD, autoimmune thyroid disease; CEL, celiac disease; CRO, Crohn's disease; IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis; MAF, minor allele frequency; MS, multiple sclerosis; OR, odds ratio; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SNP, single nucleotide polymorphism; UC, ulcerative colitis; VIT, vitiligo. * Loci newly identified by the ImmunoChip analysis (at P < 3.23 × 10 -7 ) † Evidence that SNPs in the same locus, but not necessarily the same SNP, are associated with other autoimmune disease.
SOURCE: Adapted from Reference 29, copyright © 2015 Nature Publishing Group, reprinted with permission
ACCOUNTING FOR THE GENETIC RISK OF TYPE 1 DIABETES
The genetic prediction of type 1 diabetes risk, unlike other autoimmune diseases, is relatively effective due, in part, to modest risk to relatives (8% sibling risk) and low disease prevalence (4/1,000). Following fine-mapping with the ImmunoChip, 27 MHC SNPs could account for the majority of independent additive effects in the region (tagging the classical HLA alleles) and 46 non-MHC SNPs could account for the remaining independent associations. These SNPs were used to determine the area under the Receiver Operator Using this genetic risk score in an independent set of data, the sensitivity of these 27 MHC SNPs and 46 non-MHC SNPs was 86% with a specificity of 81%. These results are consistent with those initially determined from the GWAS meta-analysis, but with greater sensitivity and specificity from novel loci detected and identification of SNPs more associated with type 1 diabetes in each locus (37) .
These estimates of sensitivity and specificity of the type 1 diabetes-associated SNPs are high, but results should be considered with caution, as they are based on Caucasian samples with well-defined case-control status and not in a clinical setting. Further, the predictive values (positive and negative) will be low, using SNPs only, as the prevalence of type 1 diabetes is low (~4/1,000). Thus, the use of genetic data to predict risk of type 1 diabetes will be useful only in the context of other (e.g., autoantibody) predictive markers. 
FROM GENE TO FUNCTION
The proximity of a disease-associated SNP to a particular gene is often thought of as providing evidence that the gene plays a role in disease pathogenesis. While this is one possible hypothesis, it is equally likely that a variant could affect the expression of one or more genes at a distance, even on other chromosomes. For many of the non-MHC type 1 diabetes-associated loci identified and fine-mapped in GWAS studies, the most significant type 1 diabetes-associated SNP is located within the transcription unit of a gene (29) ; however, in only four cases is the most associated SNP a coding variant assumed to alter the amino acid sequence of a particular gene product (rs2476601, PTPN22; rs35667974, IFIH1; rs34536443, TYK2; rs6043409, SIRPG). Findings such as these encourage functional studies of the allelic forms of the specific proteins in the four genes with coding variants to determine whether they impact pathways that could plausibly contribute to type 1 diabetes pathogenesis.
As shown by the T1DGC ImmunoChip analyses (29) , the majority of type 1 diabetes-associated SNPs are in DNA regulatory regions, specifically those regions that have clusters of transcription factors (enhancers) that have tissue-specific function. In type 1 diabetes, these cell types are those most likely relevant to autoimmunity-CD4+ T cells, CD8+ T cells, B cells, and CD34+ stem cells (29) .
Variants that affect transcription factors and enhancers require consideration of other possible mechanisms of action. These mechanisms include effects on the coding region of a previously unrecognized gene, the transcription of one or several nearby genes, or effects on genes that are distant from the most associated SNP, most recently shown as a fundamental mechanism in obesity (38, 39) . Evidence of gene-gene interaction would be suggestive of long-range regulatory effects. One approach (among many) to examining the putative functional effects of disease-associated genetic variants is to consider whether they alter the primary sequence of known regulatory motifs. As more information is obtained from functional research at the genomic level, the interpretation of the genetic variants discovered as important in type 1 diabetes will, perhaps, identify novel mechanisms of risk that can be used for prevention and therapeutic targets. Age at onset of type 1 diabetes has often been used as a simple measure of disease initiation in type 1 diabetes.
GENES AND INITIATION OF TYPE 1 DIABETES
There have been conflicting reports of possible effects of type 1 diabetes risk variants on age at onset, largely from studies of modest sample size. However, many reports have recognized the role of HLA alleles, particularly HLA-DR and HLA-DQ, on age at onset (42) , with those having onset at age <6 years more likely to have the HLA-DR3 allele and the HLA-DR3/DR4 genotype. The association of type 1 diabetes-associated SNPs with age at onset was reexamined utilizing information on risk variants identified from GWAS and fine-mapping studies, as well as a sufficiently large sample size to provide adequate statistical power to test for interaction effects (43) . Two loci, RNLS at 10q23.31 and IL2 at 4q27, displayed significant associations with age at onset. For IL2/4q27, the G allele for the rs2069763 variant is "protective," so the age at diagnosis increases with the number of protective alleles (mean age at diagnosis for those with the TT genotype is 8.7 years, the GT genotype 9.0 years, and the GG genotype 9.3 years). This effect is seen similarly for the RNLS/10q23.3 rs10500540 variant, in that the mean age at diagnosis increases with the number of protective C alleles (mean age at diagnosis for those with the TT genotype is 8.9 years, the TC genotype 9.3 years, and the CC genotype 9.4 years). Future studies of the genetics of type 1 diabetes need to focus on the relationship of genotype and phenotype, elucidating the immediate effects of individual risk variants on the relevant genes, the cellular effects of modulating the function or expression of these genes, and, most importantly, the organismic effects of such changes at the level of the patients. These studies, building upon unbiased searches for risk genes and variants hold the promise of providing both novel insights into the pathogenesis of type 1 diabetes and targets for potential preventive therapies.
CONCLUSIONS

